Last updated: May 25, 2026
Cinacalcet Hydrochloride Suppliers: Who Manufactures, Supplies, and Sources API and Finished Dose Worldwide
Cinacalcet hydrochloride supply is anchored by a small set of companies with capabilities in (1) cinacalcet API manufacture and (2) finished-dose production for branded products and generics. Practical sourcing in the market splits into two tiers: API makers that feed multiple finished-dose manufacturers, and contract manufacturers that package tablets under brand or generic labeling.
Because “suppliers” can mean different points in the value chain (API, intermediates, finished dosage, or logistics), the supplier map below is organized by role: API, finished-dose manufacturing, and pharma sourcing channels.
What companies supply cinacalcet hydrochloride API?
Cinacalcet API is manufactured by specialized small-molecule API producers, typically via proprietary routes that control impurities and polymorph/crystal form. Finished-dose tablets often use sourced API rather than integrated production.
API supply: typical supplier categories
- API manufacturers (cinacalcet hydrochloride active ingredient)
- Intermediate suppliers (key intermediates and advanced intermediates)
- API distribution platforms (global pharma chemical wholesalers serving generics and CDMOs)
How to identify cinacalcet API suppliers in practice
- Look for API DMF holders and API listing in regulatory dossiers submitted to FDA and other agencies.
- Cross-check labeling and the “Manufactured for” / “Distributed by” statements on cinacalcet tablets.
- Use supplier qualification documentation commonly requested by finished-dose manufacturers (CoA/CoO, impurity profile, particle size, polymorph confirmation).
Which companies manufacture cinacalcet hydrochloride tablets (finished dose)?
Finished-dose manufacturing is typically done by CDMOs or branded/generic formulators that buy API and perform tablet compression, coating, packaging, and quality control.
Key finished-dose manufacturing patterns
- Brand supply: branded cinacalcet hydrochloride tablets are manufactured under commercial supply contracts with dedicated facilities.
- Generic supply: multiple generic labelers use overlapping CDMO networks, often resulting in identical manufacturing sites across multiple NDCs.
What to review on product labels
- Manufacturer name and site address for the “manufactured by” or “distributed by” entities
- NDC-level mapping: the same labeler with multiple package sizes often shares the same manufacturing site
- UPC/labeler changes that indicate alternative manufacturing sources
What suppliers feed the US market for cinacalcet hydrochloride?
US supply is driven by:
- API availability from DMF-backed manufacturers
- Finished-dose production for approved ANDAs (including authorized generics or multiple labelers)
- Drug product distribution networks for chronic therapies (pharmacy supply chains)
US sourcing channels to check
- Contract manufacturing organizations producing ANDA-labeled cinacalcet tablets
- Authorized distribution agreements for FDA-approved suppliers
- Generic labelers that publish manufacturing site details on package inserts and label data
How does cinacalcet hydrochloride supply differ between brand and generics?
Brand supply
- Brand manufacturers rely on qualified commercial API and tablet manufacturing sites with long-term contracts.
- Brand product supply tends to be more stable, with less frequent site changes.
Generic supply
- Generic availability often improves redundancy because multiple ANDA products can be produced by different CDMOs.
- Generic supply may still be vulnerable to API-level disruptions if several products depend on a common API source.
What are the biggest supplier risks for cinacalcet hydrochloride?
Supply risk usually concentrates in:
- API production constraints (capacity, impurity excursions, solvent/polymorph control)
- Raw material/intermediate availability (upstream disruptions)
- Regulatory and quality changes at API or tablet manufacturing sites
- Logistics constraints (temperature/humidity controls for certain packaging formats)
Operational red flags used in procurement
- Sudden CoA impurity limit changes or different impurity spectra
- Polymorph/crystal form inconsistencies
- Manufacturing site changes that appear across multiple labelers simultaneously
- Lead-time elongation paired with limited batch release evidence
Which regions have the strongest supply base for cinacalcet hydrochloride?
Cinacalcet is typically sourced from global small-molecule manufacturing hubs:
- Asia-based API and intermediate production
- Global CDMO networks across North America, Europe, and Asia for finished-dose manufacturing
- Distributors with multi-warehouse coverage for US and EU distribution
What documents define qualification of cinacalcet hydrochloride suppliers?
Procurement qualification for cinacalcet hydrochoride typically includes:
- Regulatory: DMF references (API), site inspection status (tablet)
- Chemistry: impurity profile, residual solvent levels, particle size, polymorph/crystal form
- Quality: batch release CoA, stability data, method validation summary
- Supply: GMP/ISO certifications, change-control commitments, continuity commitments
How many supplier options exist for cinacalcet hydrochloride API and finished dose?
The market generally has:
- Multiple finished-dose manufacturers across ANDA products
- Fewer API producers relative to finished-dose labelers, because API production is more specialized and heavily controlled through filings and qualification
This structure creates a dependency chain where several finished-dose suppliers converge on a smaller API supplier set.
What supplier strategies reduce cinacalcet hydrochloride supply disruption?
- Dual sourcing at API and drug product levels
- Lot-by-lot verification for impurity spectrum and crystal form
- Contract terms that require continuity and defined “last time buy” behaviors
- Pre-qualification of alternate tablet manufacturing sites and packaging configurations
Key Takeaways
- Cinacalcet hydrochloride supply is layered: API makers supply finished-dose manufacturers and generic labelers.
- Supplier risk is concentrated at the API level and at a smaller set of tablet manufacturing sites that serve multiple NDCs.
- Strong procurement reduces exposure by dual sourcing, lot verification, and contract continuity clauses.
FAQs
Who are the common distributors for cinacalcet hydrochloride in the supply chain?
Drug wholesalers and specialty pharma chemical distributors that serve generics and CDMOs, typically holding multiple supplier relationships at the API and intermediate levels.
How do manufacturers qualify an alternate cinacalcet hydrochloride API supplier?
Through regulatory dossier alignment (DMF or equivalent), analytical comparability (impurities, residual solvents, polymorph), and GMP quality system review before commercial release.
What tablet manufacturing changes most often require regulatory updates for cinacalcet generics?
Changes involving API source, manufacturing site, critical process parameters (mixing/granulation/compression/coating), and packaging configuration can trigger regulatory updates depending on comparability outcomes.
Can cinacalcet hydrochloride generics use the same API as branded products?
Often yes, when API suppliers are qualified across multiple regulatory submissions and finished-dose manufacturers use compliant sourcing; the deciding factor is dossier and quality system alignment.
What causes cinacalcet hydrochloride shortages in practice?
API capacity constraints, impurity excursions, upstream intermediate disruptions, and quality/regulatory actions at a manufacturing site.
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Cinacalcet hydrochloride). U.S. Food and Drug Administration.
- FDA. Drug Master Files (DMFs) database and associated guidance. U.S. Food and Drug Administration.
- FDA. ANDA approval letters and product labeling resources for cinacalcet hydrochloride. U.S. Food and Drug Administration.
